Stock listing
Shattuck Labs, Inc.
Selected listing: STTK · NASDAQ · USD · US
Shattuck Labs, Inc. (NASDAQ:STTK), Health Technology. Latest release Oct 1, 2026: Shattuck Labs Announces Phase 2 Clinical Trial of SL-325 in Hidradenitis…
- Ticker
- NASDAQ:STTK
- Asset type
- Stock
- Sector
- Health Technology
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
About Shattuck Labs, Inc.
Shattuck Labs, Inc. is a public company traded under the ticker STTK in the American market. Shattuck Labs focuses on innovative approaches in the biotechnology sector.
Latest news from Shattuck Labs, Inc.
Shattuck Labs Announces Phase 2 Clinical Trial of SL-325 in Hidradenitis Suppurativa and Appointment of Shoba Ravichandran, M.D., as Senior Vice President, Clinical Development
September 30, 2026
Shattuck Labs Announces Phase 2 Clinical Trial of SL-325 in Hidradenitis Suppurativa and Appointment of Shoba Ravichandran, M.D., as Senior Vice President, Clinical Development
October 1, 2026
Shattuck Labs Announces Participation in Upcoming September Investor Conferences
September 2, 2026
Shattuck Labs Reports Second Quarter 2026 Financial Results and Recent Business Highlights
August 11, 2026
Shattuck Labs, Inc. Announces Pricing of $75 Million Public Offering
June 10, 2026
Events
Replays
Shattuck Labs, Inc. (STTK) Q3 2023 Earnings Call
Thu, Nov 09, 2023 · 08:00 AM ET
Watch